Efficacy of Cilostazol in Prevention of Peripheral Neuropathy

Inclusion Criteria

• •1. Breast cancer patients who will receive paclitaxel post-anthracycline therapy.
• •2. Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2.
• •3. Adequate bone marrow function (white blood count ≥4,000/mm3, platelet count≥100,000/mm3), liver function (serum total bilirubin \<1.5 mg/dl), renal function (creatinine \< 1.5 mg/dl).